Skip to main content

Erasca, Inc. (ERAS)

NASDAQ: ERAS · IEX Real-Time Price · USD
19.06 -0.20 (-1.04%)
Oct 21, 2021 12:59 PM EDT - Market open
Market Cap2.21B
Revenue (ttm)n/a
Net Income (ttm)-96.02M
Shares Out116.14M
EPS (ttm)-0.83
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume64,785
Open19.14
Previous Close19.26
Day's Range18.50 - 19.79
52-Week Range14.51 - 24.47
Betan/a
AnalystsBuy
Price Target30.20 (+58.4%)
Est. Earnings DateOct 28, 2021

About ERAS

Erasca is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Molecular alterations in RAS and the MAPK pathway account for approximately 5.5 million new cases of cancer worldwide per year. We have assembled what we believe to be the deepest, wholly-owned or controlled RAS/MAPK pathway-focused pipeline in the industry, comprising 11 modality-agnostic programs aligned with our three therapeutic strategies of: (1) targeting key ...

IndustryBiotechnology
IPO DateJul 16, 2021
CEOJonathan E. Lim, M.D.
Employees102
Stock ExchangeNASDAQ
Ticker SymbolERAS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for Erasca stock is "Buy." The 12-month stock price forecast is 30.20, which is an increase of 58.45% from the latest price.

Price Target
$30.20
(58.45% upside)
Analyst Consensus: Buy

News

Erasca is Named One of Fierce Biotech's “Fierce 15” Biotechnology Companies of 2021

SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for pa...

3 weeks ago - GlobeNewsWire

Erasca (ERAS) Inks Deal With Pfizer for Colorectal Cancer Study

Erasca (ERAS) signs an agreement with Pfizer for a clinical study, which will evaluate ERAS-007 in combination with encorafenib and cetuximab for BRAF V600E-mutant metastatic colorectal cancer.

Other symbols:PFE
1 month ago - Zacks Investment Research

Erasca Announces First Patient Dosed in HERKULES-2 Phase 1b/2 Lung Cancer Master Protocol Evaluating ERAS-007 in Mult...

ERAS-007, a potential best-in-class ERK1/2 inhibitor, is believed to have broad therapeutic applicability across a wide range of tumor types and indications ERAS-007, a potential best-in-class ERK1/2 in...

1 month ago - GlobeNewsWire

Erasca Reports Second Quarter 2021 Financial Results and Business Updates

Successfully closed $345 million upsized IPO in July 2021

1 month ago - GlobeNewsWire

Erasca Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ...

SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for pat...

3 months ago - GlobeNewsWire

Erasca Announces Pricing of Upsized Initial Public Offering

SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for pat...

3 months ago - GlobeNewsWire

Erasca IPO Registration Document (S-1)

Erasca, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC